Stay updated on Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and tolerability comparison of irreversible electroporation in combination with Nivolumab for patients with locally advanced pancreatic cancer.
    Difference
    0.2%
    Check dated 2024-06-06T14:29:52.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health condition, and prior treatments. This change provides more specific information about who can participate in the study, including inclusion and exclusion criteria.
    Difference
    16%
    Check dated 2024-05-22T20:57:11.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:15:27.000Z thumbnail image

Stay in the know with updates to Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page.